Compare Ascendis Pharma A/S (ASND) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Qurate Retail Inc Series A — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Qurate Retail Inc Series A trades at $0.09 (market cap $974.68K). The key difference: Ascendis Pharma A/S is far larger — about 18200.8× Qurate Retail Inc Series A's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| ASND | QVCAQ | |
|---|---|---|
Market Cap | $17.74B | $974.68K |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $15.03 |
52-Week Low | $163.32 | $0.07 |
Enterprise Value | $18.11B | $4.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
QVCAQ trades at $0.0911, down 10.69% on the day, reflecting persistent bearish sentiment. The stock shows mixed earnings performance with one beat and three misses in recent quarters, while financials reveal declining revenue and negative net income margins. Cash flow trends are volatile, with significant financing activities offsetting weak operations. The balance sheet indicates negative shareholder equity and rising debt-to-asset ratios, signaling financial stress. Recent news highlights QVC's 40th anniversary and partnership with TikTok Shop, aiming to revitalize its live shopping brand.
The outlook remains challenging due to sustained losses, high leverage, and competitive pressures in retail. Investment opportunities are limited without a clear path to profitability, though low P/B and P/E ratios may attract value hunters. Key risks include liquidity constraints, debt servicing burdens, and execution missteps in digital transformation efforts. Investors should await concrete turnaround evidence before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
